ES2301859T3 - Nuevos derivados de piridazin-3(2h)-ona. - Google Patents
Nuevos derivados de piridazin-3(2h)-ona. Download PDFInfo
- Publication number
- ES2301859T3 ES2301859T3 ES03782471T ES03782471T ES2301859T3 ES 2301859 T3 ES2301859 T3 ES 2301859T3 ES 03782471 T ES03782471 T ES 03782471T ES 03782471 T ES03782471 T ES 03782471T ES 2301859 T3 ES2301859 T3 ES 2301859T3
- Authority
- ES
- Spain
- Prior art keywords
- alkyl
- amino
- mono
- alkoxy
- group
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 125000000008 (C1-C10) alkyl group Chemical group 0.000 abstract 31
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 abstract 19
- 125000000027 (C1-C10) alkoxy group Chemical group 0.000 abstract 13
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 abstract 12
- 125000001424 substituent group Chemical group 0.000 abstract 10
- 125000005843 halogen group Chemical group 0.000 abstract 9
- 125000002887 hydroxy group Chemical group [H]O* 0.000 abstract 9
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 abstract 7
- 125000003837 (C1-C20) alkyl group Chemical group 0.000 abstract 6
- 125000004397 aminosulfonyl group Chemical group NS(=O)(=O)* 0.000 abstract 6
- 125000001951 carbamoylamino group Chemical group C(N)(=O)N* 0.000 abstract 6
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 abstract 6
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 abstract 6
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 6
- 125000000446 sulfanediyl group Chemical group *S* 0.000 abstract 6
- 125000003161 (C1-C6) alkylene group Chemical group 0.000 abstract 5
- 125000004442 acylamino group Chemical group 0.000 abstract 5
- ORTFAQDWJHRMNX-UHFFFAOYSA-N hydroxidooxidocarbon(.) Chemical group O[C]=O ORTFAQDWJHRMNX-UHFFFAOYSA-N 0.000 abstract 5
- 241000790917 Dioxys <bee> Species 0.000 abstract 4
- 125000002252 acyl group Chemical group 0.000 abstract 4
- 125000000217 alkyl group Chemical group 0.000 abstract 4
- 125000004104 aryloxy group Chemical group 0.000 abstract 4
- -1 hydroxycarbonyl groups Chemical group 0.000 abstract 4
- 125000004093 cyano group Chemical group *C#N 0.000 abstract 3
- 125000001072 heteroaryl group Chemical group 0.000 abstract 3
- 125000005842 heteroatom Chemical group 0.000 abstract 3
- 229910052757 nitrogen Inorganic materials 0.000 abstract 3
- 125000004043 oxo group Chemical group O=* 0.000 abstract 3
- 229910052760 oxygen Inorganic materials 0.000 abstract 3
- 229910052717 sulfur Inorganic materials 0.000 abstract 3
- 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 abstract 3
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 abstract 3
- 125000003277 amino group Chemical group 0.000 abstract 2
- 125000003118 aryl group Chemical group 0.000 abstract 2
- 125000000000 cycloalkoxy group Chemical group 0.000 abstract 2
- 125000002950 monocyclic group Chemical group 0.000 abstract 2
- 125000003367 polycyclic group Chemical group 0.000 abstract 2
- 125000000475 sulfinyl group Chemical group [*:2]S([*:1])=O 0.000 abstract 2
- 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 abstract 2
- 125000000229 (C1-C4)alkoxy group Chemical group 0.000 abstract 1
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 abstract 1
- 125000006708 (C5-C14) heteroaryl group Chemical group 0.000 abstract 1
- AAILEWXSEQLMNI-UHFFFAOYSA-N 1h-pyridazin-6-one Chemical class OC1=CC=CN=N1 AAILEWXSEQLMNI-UHFFFAOYSA-N 0.000 abstract 1
- 150000001204 N-oxides Chemical class 0.000 abstract 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 abstract 1
- 125000003545 alkoxy group Chemical group 0.000 abstract 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 abstract 1
- 125000004432 carbon atom Chemical group C* 0.000 abstract 1
- 125000000392 cycloalkenyl group Chemical group 0.000 abstract 1
- 125000000753 cycloalkyl group Chemical group 0.000 abstract 1
- 125000004786 difluoromethoxy group Chemical group [H]C(F)(F)O* 0.000 abstract 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 1
- 125000002768 hydroxyalkyl group Chemical group 0.000 abstract 1
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 abstract 1
- 125000004433 nitrogen atom Chemical group N* 0.000 abstract 1
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 abstract 1
- 239000001301 oxygen Chemical group 0.000 abstract 1
- 125000004076 pyridyl group Chemical group 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 239000011593 sulfur Chemical group 0.000 abstract 1
- 125000001544 thienyl group Chemical group 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
- C07D237/02—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
- C07D237/06—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
- C07D237/10—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D237/24—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
Abstract
Un derivado de piridazin-3(2H)-ona de fórmula (I): (Ver fórmula) en la que R1 representa un grupo seleccionado de: * un grupo alquilo C1-C4 que está opcionalmente sustituido con uno o más; y * grupos de fórmula -(CH2)n-R6 en la que n es un número entero que varía de 1 a 3 y R6 representa un grupo cicloalquilo C3-C6, R2 es un átomo de hidrógeno, R3 representa un grupo arilo C5-C14 monocíclico o policíclico o un grupo heteroarilo de 5 a 14 miembros que contiene al menos un heteroátomo seleccionado de O, S y N, que está opcionalmente sustituido con uno o más, por ejemplo 1, 2, 3 ó 4 sustituyentes seleccionados de: * átomos de halógeno; * grupos alquilo C1-C20 y alquileno C1-C6, que están opcionalmente sustituidos con uno o más sustituyentes seleccionados de átomos de halógeno; y grupos fenilo, hidroxi, hidroxialquilo C1-C10, alcoxi C1-C10, ariloxi C5-C14, (alquil C1-C10)tio, oxo, amino, mono- o di-(alquil C1-C10)amino, acilamino, hidroxicarbonilo, (alcoxi C1-C10)carbonilo, carbamoilo, mono- o di-(alquil C1-C10)carbamoilo * grupos fenilo, hidroxi, hidroxialquilo C1-C10, alcoxi C1-C10, cicloalcoxi C3-C7, nitro, ariloxi C5-C14, (alquil C1-C10)tio, (alquil C1-C10)sulfinilo, (alquil C1-C10)sulfonilo, (alquil C1-C10)sulfamoilo, acilo, amino, mono- o di(alquil C1-C10)amino, acilamino, hidroxicarbonilo, (alcoxi C1-C10)carbonilo, carbamoilo, mono- o di(alquil C1-C10)carbamoilo, ureido, N''-(alquil C1-C10)ureido, N'',N''-di(alquil C1-C10)ureido, (alquil C1-C10)sulfamido, aminosulfonilo, mono- o di(alquil C1-C10)aminosulfonilo, ciano, difluorometoxi o trifluorometoxi; R5 representa un grupo -COOR7 o un grupo arilo C5-C14 monocíclico o policíclico o un grupo heteroarilo de 5 a 14 miembros que contiene al menos un heteroátomo seleccionado de O, S y N, que está opcionalmente sustituido con uno o más sustituyentes seleccionados de: * átomos de halógeno; * grupos alquilo C1-C20 y alquileno C2-C20, que están opcionalmente sustituidos con uno o más sustituyentes seleccionados de átomos de halógeno y grupos fenilo, hidroxi, hidroxialquilo C1-C10, alcoxi C1-C10, ariloxi C5-C14, (alquil C1-C10)tio, oxo, amino, mono- o di-(alquil C1-C10)amino, acilamino, hidroxicarbonilo, (alcoxi C1-C10)carbonilo, carbamoilo, mono- o di(alquil C1-C10)carbamoilo; y * grupos fenilo, hidroxi, (alquileno C1-C6)dioxi, alcoxi C1-C10, cicloalcoxi C3-C7, nitro, (alquil C1-C10)tio, (alquil C1-C10)sulfinilo, (alquil C1-C10)sulfonilo, (alquil C1-C10)sulfamoilo, amino, mono- o di(alquil C1-C10)amino, acilamino, nitro, acilo, hidroxicarbonilo, (alcoxi C1-C10)carbonilo, carbamoilo, mono- o di(alquil C1-C10)carbamoilo, ureido, N''-(alquil C1-C10)ureido, N'',N''-di(alquil C1-C10)ureido, (alquil C1-C10)sulfamido, aminosulfonilo, mono- o di(alquil C1-C10)aminosulfonilo, ciano, difluorometoxi o trifluorometoxi; en el que R7 representa un alquilo C1-C20 que está opcionalmente sustituido con uno o más sustituyentes seleccionados de átomos de halógeno y grupos hidroxi, alcoxi C1-C10, ariloxi C5-C14, (alquil C1-C10)tio, oxo, amino, mono- o di(alquil C1-C10)amino, acilamino, hidroxicarbonilo, (alcoxi C1-C10)carbonilo, carbamoilo, mono- o di-(alquil C1-C10)carbamoilo o un grupo de fórmula -(CH2)m-R11 en la que m es un número entero de 0 a 4 y R11 representa: * un grupo cicloalquilo C3-C7 o cicloalquenilo C3-C7; * un grupo arilo C5-C14, que está opcionalmente sustituido con uno o más sustituyentes seleccionados de átomos de halógeno y grupos alquilo C1-C20, hidroxi, alcoxi C1-C10, (alquileno C1-C6)dioxi, (alquil C1-C10)tio, amino, mono- o di(alquil C1-C10)amino, nitro, acilo, hidroxicarbonilo, (alcoxi C1-C10)carbonilo, carbamoilo, mono- o di-(alquil C1-C10)carbamoilo, ciano, trifluorometilo, difluorometoxi o trifluorometoxi; * o un anillo de 3 a 7 miembros que comprende de 1 a 4 heteroátomos seleccionados de nitrógeno, oxígeno y azufre, anillo que puede estar opcionalmente sustituido con uno o más sustituyentes seleccionados de átomos de halógeno y grupos alquilo C1-C20, hidroxi, alcoxi C1-C10, (alquileno C1-C6)dioxi, amino, mono- o di(alquil C1-C10)amino, nitro, ciano o trifluorometilo; y R4 representa * un grupo alquilo que tiene de 1 a 6 átomos de carbono y que está opcionalmente sustituido con uno o más sustituyentes seleccionados de átomos de halógeno y grupo hidroxi; * un grupo mono-(alquil C1-C4)amino o di-(alquil C1-C4)amino no sustituido; * un grupo alquilo C1-C4 que está no sustituido o sustituido con uno o más sustituyentes seleccionados de grupos hidroxi, alcoxi C1-C4, amino, mono(alquil C1-C4)amino y di(alquil C1-C4)amino; * un grupo fenil(alquilo C1-C4)- no sustituido; o * un grupo de fórmula -(CH2)p-R12 en la que p es 2 y R12 representa un radical seleccionado de fenilo, piridilo y tienilo opcionalmente sustituido con uno o más sustituyentes seleccionados de átomos de halógeno y grupos alquilo C1-C20, hidroxi, alcoxi C1-C10, (alquileno C1-C6)dioxi, amino, mono- o di(alquil C1-C10)amino, nitro, ciano y trifluorometilo, siendo cada resto acilo en R3, R5 y R11 un radical C2-C20 unido a un radical carbonilo; asi como los N-óxidos obtenibles de los radicales heteroarilo presentes en la estructura cuando dichos radicales comprenden átomos de nitrógeno y sus sales farmacéuticamente aceptables, con la condición de que cuando R5 no es un grupo heteroarilo opcionalmente sustituido ni un grupo COOR7, entonces R3 es un grupo heteroarilo opcionalmente sustituido.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
ES200203003A ES2211344B1 (es) | 2002-12-26 | 2002-12-26 | Nuevos derivados de piridazin-3(2h)-ona. |
ES200203003 | 2002-12-26 |
Publications (1)
Publication Number | Publication Date |
---|---|
ES2301859T3 true ES2301859T3 (es) | 2008-07-01 |
Family
ID=32669111
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ES200203003A Expired - Fee Related ES2211344B1 (es) | 2002-12-26 | 2002-12-26 | Nuevos derivados de piridazin-3(2h)-ona. |
ES03782471T Expired - Lifetime ES2301859T3 (es) | 2002-12-26 | 2003-12-22 | Nuevos derivados de piridazin-3(2h)-ona. |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ES200203003A Expired - Fee Related ES2211344B1 (es) | 2002-12-26 | 2002-12-26 | Nuevos derivados de piridazin-3(2h)-ona. |
Country Status (30)
Country | Link |
---|---|
US (2) | US7491722B2 (es) |
EP (1) | EP1575926B1 (es) |
JP (1) | JP4679154B2 (es) |
KR (1) | KR20050087868A (es) |
CN (1) | CN100443474C (es) |
AR (1) | AR042665A1 (es) |
AT (1) | ATE388140T1 (es) |
AU (1) | AU2003290110B2 (es) |
BR (1) | BR0316883A (es) |
CA (1) | CA2512099A1 (es) |
CL (1) | CL2003002746A1 (es) |
CY (1) | CY1107978T1 (es) |
DE (1) | DE60319584T2 (es) |
DK (1) | DK1575926T3 (es) |
EC (1) | ECSP055883A (es) |
ES (2) | ES2211344B1 (es) |
HK (1) | HK1075629A1 (es) |
MX (1) | MXPA05006809A (es) |
MY (1) | MY140725A (es) |
NO (1) | NO20053614L (es) |
NZ (1) | NZ540762A (es) |
PE (1) | PE20040937A1 (es) |
PT (1) | PT1575926E (es) |
RU (1) | RU2346939C2 (es) |
SI (1) | SI1575926T1 (es) |
TW (1) | TWI287545B (es) |
UA (1) | UA80016C2 (es) |
UY (1) | UY28141A1 (es) |
WO (1) | WO2004058729A1 (es) |
ZA (1) | ZA200504943B (es) |
Families Citing this family (71)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7214687B2 (en) | 1999-07-14 | 2007-05-08 | Almirall Ag | Quinuclidine derivatives and medicinal compositions containing the same |
ES2165768B1 (es) | 1999-07-14 | 2003-04-01 | Almirall Prodesfarma Sa | Nuevos derivados de quinuclidina y composiciones farmaceuticas que los contienen. |
ES2211344B1 (es) * | 2002-12-26 | 2005-10-01 | Almirall Prodesfarma, S.A. | Nuevos derivados de piridazin-3(2h)-ona. |
ES2232306B1 (es) * | 2003-11-10 | 2006-08-01 | Almirall Prodesfarma, S.A. | Nuevos derivados de piridazin-3(2h)-ona. |
DE602005022499D1 (de) | 2004-05-31 | 2010-09-02 | Almirall Sa | Kombinationen mit Antimuskarin-Wirkstoffen und PDE4-Hemmern |
ES2257152B1 (es) | 2004-05-31 | 2007-07-01 | Laboratorios Almirall S.A. | Combinaciones que comprenden agentes antimuscarinicos y agonistas beta-adrenergicos. |
ES2251866B1 (es) | 2004-06-18 | 2007-06-16 | Laboratorios Almirall S.A. | Nuevos derivados de piridazin-3(2h)-ona. |
ES2251867B1 (es) * | 2004-06-21 | 2007-06-16 | Laboratorios Almirall S.A. | Nuevos derivados de piridazin-3(2h)-ona. |
CA2584261A1 (en) * | 2004-10-13 | 2006-04-20 | Kyowa Hakko Kogyo Co., Ltd. | Pharmaceutical composition |
EP1810692A1 (en) * | 2004-10-13 | 2007-07-25 | Kyowa Hakko Kogyo Co., Ltd. | Remedies/preventives for chronic skin disease |
ES2265276B1 (es) | 2005-05-20 | 2008-02-01 | Laboratorios Almirall S.A. | Derivados de 4-(2-amino-1-hidroxietil)fenol como agonistas del receptor beta2 adrenergico. |
ES2354627T3 (es) | 2005-10-05 | 2011-03-16 | F. Hoffmann-La Roche Ag | Derivados de naftiridina. |
JO2769B1 (en) | 2005-10-26 | 2014-03-15 | جانسين فارماسوتيكا ان. في | Rapid decomposition of physiologically antagonistic agents of the 2-dopamine receptor |
KR20080094921A (ko) * | 2006-01-16 | 2008-10-27 | 우베 고산 가부시키가이샤 | 피롤로피리다지논 화합물 |
ES2298049B1 (es) | 2006-07-21 | 2009-10-20 | Laboratorios Almirall S.A. | Procedimiento para fabricar bromuro de 3(r)-(2-hidroxi-2,2-ditien-2-ilacetoxi)-1-(3-fenoxipropil)-1-azoniabiciclo (2.2.2) octano. |
JO2849B1 (en) | 2007-02-13 | 2015-03-15 | جانسين فارماسوتيكا ان. في | Dopamine 2 receptor antagonists are rapidly hydrolyzed |
ES2320955B1 (es) | 2007-03-02 | 2010-03-16 | Laboratorios Almirall S.A. | Nuevos derivados de 3-((1,2,4)triazolo(4,3-a)piridin-7-il)benzamida. |
ES2320954B1 (es) * | 2007-03-02 | 2010-03-16 | Laboratorio Almirall S.A. | Nuevo procedimiento de preparacion de 3-metil-4-fenilisoxazolo (3,4-d)iridazin-7(6h)-ona. |
PT2148873E (pt) | 2007-04-23 | 2012-11-20 | Janssen Pharmaceutica Nv | Derivados da 4-alcoxipiridazina antagonistas de dissociação rápida do recetor da dopamina 2 |
MX2009011416A (es) | 2007-04-23 | 2009-11-05 | Janssen Pharmaceutica Nv | Tia(di)azoles como antagonistas del receptor de dopamina 2 de disociacion rapida. |
EP2096105A1 (en) | 2008-02-28 | 2009-09-02 | Laboratorios Almirall, S.A. | Derivatives of 4-(2-amino-1-hydroxyethyl)phenol as agonists of the b2 adrenergic receptor |
EP2100599A1 (en) | 2008-03-13 | 2009-09-16 | Laboratorios Almirall, S.A. | Inhalation composition containing aclidinium for treatment of asthma and chronic obstructive pulmonary disease |
EP2100598A1 (en) | 2008-03-13 | 2009-09-16 | Laboratorios Almirall, S.A. | Inhalation composition containing aclidinium for treatment of asthma and chronic obstructive pulmonary disease |
EP2108641A1 (en) | 2008-04-11 | 2009-10-14 | Laboratorios Almirall, S.A. | New substituted spiro[cycloalkyl-1,3'-indo]-2'(1'H)-one derivatives and their use as p38 mitogen-activated kinase inhibitors |
EP2113503A1 (en) | 2008-04-28 | 2009-11-04 | Laboratorios Almirall, S.A. | New substituted indolin-2-one derivatives and their use as p39 mitogen-activated kinase inhibitors |
CN102171189B (zh) | 2008-07-31 | 2013-11-20 | 詹森药业有限公司 | 作为快速解离多巴胺2受体拮抗剂的哌嗪-1-基-三氟甲基取代的吡啶 |
WO2010065153A1 (en) * | 2008-12-06 | 2010-06-10 | Intra-Cellular Therapies, Inc. | Organic compounds |
EP2196465A1 (en) | 2008-12-15 | 2010-06-16 | Almirall, S.A. | (3-oxo)pyridazin-4-ylurea derivatives as PDE4 inhibitors |
UY32297A (es) | 2008-12-22 | 2010-05-31 | Almirall Sa | Sal mesilato de 5-(2-{[6-(2,2-difluoro-2-fenilitoxi) hexil]amino}-1-hidroxietil)-8-hidroxiquinolin-2( 1h)-ona como agonista del receptor b(beta)2 acrenérgico |
EP2221297A1 (en) | 2009-02-18 | 2010-08-25 | Almirall, S.A. | 5-(2-{[6-(2,2-difluoro-2-phenylethoxy)hexyl]amino}-1-hydroxyethyl)-8-hydroxyquinolin-2(1h)-one and its use in the treatment of pulmonary diseases |
EP2221055A1 (en) | 2009-02-18 | 2010-08-25 | Almirall, S.A. | 5-(2-{[6-(2,2-difluoro-2-phenylethoxy)hexyl]amino}-1-hydroxyethyl)-8-hydroxyquinolin-2(1H)-one for the treatment of lung function |
EP2228368A1 (en) | 2009-03-12 | 2010-09-15 | Almirall, S.A. | Process for manufacturing 5-(2-{[6-(2,2-difluoro-2-phenylethoxy) hexyl]amino}-1-hydroxyethyl)-8-hydroxyquinolin-2(1H)-one |
EP2322176A1 (en) | 2009-11-11 | 2011-05-18 | Almirall, S.A. | New 7-phenyl-[1,2,4]triazolo[4,3-a]pyridin-3(2H)-one derivatives |
WO2011075415A1 (en) * | 2009-12-14 | 2011-06-23 | Inspire Pharmaceuticals, Inc. | Bridged bicyclic rho kinase inhibitor compounds, composition and use |
EP2338888A1 (en) | 2009-12-24 | 2011-06-29 | Almirall, S.A. | Imidazopyridine derivatives as JAK inhibitors |
EP2528915B1 (en) * | 2010-01-29 | 2015-10-28 | Boehringer Ingelheim International GmbH | Substituted naphthyridines and their use as syk kinase inhibitors |
EP2360158A1 (en) | 2010-02-18 | 2011-08-24 | Almirall, S.A. | Pyrazole derivatives as jak inhibitors |
UY33213A (es) | 2010-02-18 | 2011-09-30 | Almirall Sa | Derivados de pirazol como inhibidores de jak |
EP2386555A1 (en) | 2010-05-13 | 2011-11-16 | Almirall, S.A. | New cyclohexylamine derivatives having beta2 adrenergic agonist and m3 muscarinic antagonist activities |
EP2394998A1 (en) * | 2010-05-31 | 2011-12-14 | Almirall, S.A. | 3-(5-Amino-6-oxo-1,6-dihydropyridazin-3-yl)-biphenyl derivatives as PDE4 inhibitors |
EP2397482A1 (en) | 2010-06-15 | 2011-12-21 | Almirall, S.A. | Heteroaryl imidazolone derivatives as jak inhibitors |
JP5790348B2 (ja) | 2010-09-08 | 2015-10-07 | 住友化学株式会社 | ピリダジノン化合物の製造法およびその製造中間体 |
EP2441755A1 (en) | 2010-09-30 | 2012-04-18 | Almirall, S.A. | Pyridine- and isoquinoline-derivatives as Syk and JAK kinase inhibitors |
EP2457900A1 (en) | 2010-11-25 | 2012-05-30 | Almirall, S.A. | New pyrazole derivatives having CRTh2 antagonistic behaviour |
EP2463289A1 (en) | 2010-11-26 | 2012-06-13 | Almirall, S.A. | Imidazo[1,2-b]pyridazine derivatives as JAK inhibitors |
EP2489663A1 (en) | 2011-02-16 | 2012-08-22 | Almirall, S.A. | Compounds as syk kinase inhibitors |
EP2510928A1 (en) | 2011-04-15 | 2012-10-17 | Almirall, S.A. | Aclidinium for use in improving the quality of sleep in respiratory patients |
EP2518070A1 (en) | 2011-04-29 | 2012-10-31 | Almirall, S.A. | Pyrrolotriazinone derivatives as PI3K inhibitors |
EP2518071A1 (en) | 2011-04-29 | 2012-10-31 | Almirall, S.A. | Imidazopyridine derivatives as PI3K inhibitors |
EP2526945A1 (en) | 2011-05-25 | 2012-11-28 | Almirall, S.A. | New CRTH2 Antagonists |
EP2527344A1 (en) | 2011-05-25 | 2012-11-28 | Almirall, S.A. | Pyridin-2(1H)-one derivatives useful as medicaments for the treatment of myeloproliferative disorders, transplant rejection, immune-mediated and inflammatory diseases |
EP2548876A1 (en) | 2011-07-18 | 2013-01-23 | Almirall, S.A. | New CRTh2 antagonists |
EP2548863A1 (en) | 2011-07-18 | 2013-01-23 | Almirall, S.A. | New CRTh2 antagonists. |
EP2554544A1 (en) | 2011-08-01 | 2013-02-06 | Almirall, S.A. | Pyridin-2(1h)-one derivatives as jak inhibitors |
EP2578570A1 (en) | 2011-10-07 | 2013-04-10 | Almirall, S.A. | Novel process for preparing 5-(2-{[6-(2,2-difluoro-2-phenylethoxy)hexyl]amino}-1(r)-hydroxyethyl)-8-hydroxyquinolin-2(1h)-one via novel intermediates of synthesis. |
EP2592078A1 (en) | 2011-11-11 | 2013-05-15 | Almirall, S.A. | New cyclohexylamine derivatives having beta2 adrenergic agonist and M3 muscarinic antagonist activities |
EP2592077A1 (en) | 2011-11-11 | 2013-05-15 | Almirall, S.A. | New cyclohexylamine derivatives having beta2 adrenergic agonist and M3 muscarinic antagonist activities |
EP2641900A1 (en) | 2012-03-20 | 2013-09-25 | Almirall, S.A. | Novel polymorphic Crystal forms of 5-(2-{[6-(2,2-difluoro-2-phenylethoxy) hexyl]amino}-1-(R)-hydroxyethyl)-8-hydroxyquinolin-2(1h)-one, heminapadisylate as agonist of the ß2 adrenergic receptor. |
EP2647627A1 (en) | 2012-04-02 | 2013-10-09 | Almirall, S.A. | Salts of 5-[(1r)-2-({2-[4-(2,2-difluoro-2-phenylethoxy)phenyl] ethyl}amino)-1-hydroxyethyl]-8-hydroxyquinolin-2(1h)-one. |
EP2666465A1 (en) | 2012-05-25 | 2013-11-27 | Almirall, S.A. | Novel dosage and formulation |
EP2668941A1 (en) | 2012-05-31 | 2013-12-04 | Almirall, S.A. | Novel dosage form and formulation of abediterol |
WO2014060431A1 (en) | 2012-10-16 | 2014-04-24 | Almirall, S.A. | Pyrrolotriazinone derivatives as pi3k inhibitors |
EP2738172A1 (en) | 2012-11-28 | 2014-06-04 | Almirall, S.A. | New bicyclic compounds as crac channel modulators |
CN104869996A (zh) | 2012-12-17 | 2015-08-26 | 阿尔米雷尔有限公司 | 阿地铵的新用途 |
EA201500651A1 (ru) | 2012-12-18 | 2015-11-30 | Альмираль, С.А. | НОВЫЕ ПРОИЗВОДНЫЕ ЦИКЛОГЕКСИЛ- И ХИНУКЛИДИНИЛКАРБАМАТА, ОБЛАДАЮЩИЕ АГОНИСТИЧЕСКОЙ АКТИВНОСТЬЮ ПО ОТНОШЕНИЮ К β2 АДРЕНЕРГИЧЕСКОМУ РЕЦЕПТОРУ И АНТАГОНИСТИЧЕСКОЙ АКТИВНОСТЬЮ ПО ОТНОШЕНИЮ К МУСКАРИНОВОМУ РЕЦЕПТОРУ М3 |
AR094797A1 (es) | 2013-02-15 | 2015-08-26 | Almirall Sa | Derivados de pirrolotriazina como inhibidores de pi3k |
WO2014139150A1 (en) * | 2013-03-15 | 2014-09-18 | Merck Sharp & Dohme Corp. | Substituted pyridizinone derivatives as pde10 inhibitors |
EP2848615A1 (en) | 2013-07-03 | 2015-03-18 | Almirall, S.A. | New pyrazole derivatives as CRAC channel modulators |
LT3640241T (lt) | 2013-10-18 | 2022-12-27 | Celgene Quanticel Research, Inc. | Bromodomeno inhibitoriai |
JP2021527125A (ja) * | 2018-06-07 | 2021-10-11 | ディサーム・セラピューティクス・インコーポレイテッドDisarm Therapeutics, Inc. | Sarm1阻害剤 |
KR102481635B1 (ko) * | 2020-09-28 | 2022-12-26 | 서울대학교산학협력단 | 메타-치환된 니코틴 유도체의 신규 합성방법 |
Family Cites Families (24)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB1351569A (en) | 1972-05-15 | 1974-05-01 | Morishita Pharma | 2-alkyl-4-alkoxy-5-morpholino-3-2h-pyridazinones and their method of preparation |
DE2225218C2 (de) | 1972-05-24 | 1983-01-13 | Morishita Pharmaceutical Co., Ltd., Osaka | 2-Alkyl-4-äthoxy-5-morpholino-3(2H)-pyridazinone und Verfahren zu deren Herstellung |
HUT66969A (en) * | 1991-10-09 | 1995-01-30 | Syntex Inc | Benzo- and pyrido-pyridazinone- and pyridazin-thion derivatives, pharmaceutical compositions containing the same and process for the production of thereof |
US5679696A (en) * | 1992-07-28 | 1997-10-21 | Rhone-Poulenc Rorer Limited | Compounds containing phenyl linked to aryl or heteroaryl by an aliphatic-or heteroatom-containing linking group |
DE19533975A1 (de) * | 1995-09-14 | 1997-03-20 | Merck Patent Gmbh | Arylalkyl-diazinone |
DE19540475A1 (de) * | 1995-10-20 | 1997-04-24 | Schering Ag | Chirale Methylphenyloxazolidinone |
KR20000065219A (ko) * | 1996-05-20 | 2000-11-06 | 마르크 젠너 | 티엔에프 저해제 및 피디이-4 저해제로서의 퀴놀린 카르복사미드 |
ES2137113B1 (es) | 1997-07-29 | 2000-09-16 | Almirall Prodesfarma Sa | Nuevos derivados de triazolo-piridazinas heterociclicos. |
US6162830A (en) * | 1997-11-25 | 2000-12-19 | Warner-Lambert Company | Benzenesulfonamide inhibitors of PDE-IV and their therapeutic use |
CZ300570B6 (cs) * | 1998-10-27 | 2009-06-17 | Abbott Laboratories | Inhibitory biosyntézy prostaglandin endoperoxid H synthasy |
AU764005B2 (en) * | 1999-02-25 | 2003-08-07 | Merck Frosst Canada & Co. | PDE IV inhibiting compounds, compositions and methods of treatment |
US6313156B1 (en) | 1999-12-23 | 2001-11-06 | Icos Corporation | Thiazole compounds as cyclic-AMP-specific phosphodiesterase inhibitors |
US6699890B2 (en) * | 2000-12-22 | 2004-03-02 | Memory Pharmaceuticals Corp. | Phosphodiesterase 4 inhibitors |
RU2340600C2 (ru) * | 2001-10-16 | 2008-12-10 | Мемори Фармасьютиклз Корпорейшн | Производные 4-(4-алкокси-3-гидроксифенил)-2-пирролидона в качестве ингибиторов pde-4 для лечения неврологических синдромов |
MY130622A (en) * | 2001-11-05 | 2007-07-31 | Novartis Ag | Naphthyridine derivatives, their preparation and their use as phosphodiesterase isoenzyme 4 (pde4) inhibitors |
US6972936B2 (en) * | 2002-03-29 | 2005-12-06 | Robert Allan Morris | Pre-emptive circuit breaker with arc fault and fault lockout short circuit protection |
ES2195785B1 (es) * | 2002-05-16 | 2005-03-16 | Almirall Prodesfarma, S.A. | Nuevos derivados de piridazin-3(2h)-ona. |
BR0315705A (pt) * | 2002-11-19 | 2005-09-06 | Memory Pharm Corp | Inibidores de fosfodiesterase-4 |
ES2211344B1 (es) * | 2002-12-26 | 2005-10-01 | Almirall Prodesfarma, S.A. | Nuevos derivados de piridazin-3(2h)-ona. |
BRPI0409888A (pt) * | 2003-04-18 | 2006-05-23 | Memory Pharm Corp | derivados de pirazol como inibidores de fosfodiesterase 4, composto, composição farmacêutica, método para efetuar a inibição da enzima pde4, incrementar a cognição e/ou tratar a psicose em um paciente, método para o tratamento de um paciente que tem uma doença que envolve nìveis de camp diminuìdos, método para o tratamento de um paciente que sofre de uma doença alérgica ou inflamatória e método para o tratamento de um paciente que sofre de neurodegeneração resultante de uma doença ou de um ferimento |
ES2232306B1 (es) | 2003-11-10 | 2006-08-01 | Almirall Prodesfarma, S.A. | Nuevos derivados de piridazin-3(2h)-ona. |
ES2251866B1 (es) * | 2004-06-18 | 2007-06-16 | Laboratorios Almirall S.A. | Nuevos derivados de piridazin-3(2h)-ona. |
ES2251867B1 (es) * | 2004-06-21 | 2007-06-16 | Laboratorios Almirall S.A. | Nuevos derivados de piridazin-3(2h)-ona. |
ES2320954B1 (es) * | 2007-03-02 | 2010-03-16 | Laboratorio Almirall S.A. | Nuevo procedimiento de preparacion de 3-metil-4-fenilisoxazolo (3,4-d)iridazin-7(6h)-ona. |
-
2002
- 2002-12-26 ES ES200203003A patent/ES2211344B1/es not_active Expired - Fee Related
-
2003
- 2003-12-19 UY UY28141A patent/UY28141A1/es unknown
- 2003-12-22 MX MXPA05006809A patent/MXPA05006809A/es active IP Right Grant
- 2003-12-22 SI SI200331196T patent/SI1575926T1/sl unknown
- 2003-12-22 DK DK03782471T patent/DK1575926T3/da active
- 2003-12-22 AU AU2003290110A patent/AU2003290110B2/en not_active Ceased
- 2003-12-22 DE DE60319584T patent/DE60319584T2/de not_active Expired - Lifetime
- 2003-12-22 CA CA002512099A patent/CA2512099A1/en not_active Abandoned
- 2003-12-22 BR BR0316883-2A patent/BR0316883A/pt not_active IP Right Cessation
- 2003-12-22 US US10/539,821 patent/US7491722B2/en not_active Expired - Fee Related
- 2003-12-22 RU RU2005123484/04A patent/RU2346939C2/ru not_active IP Right Cessation
- 2003-12-22 UA UAA200507288A patent/UA80016C2/uk unknown
- 2003-12-22 AT AT03782471T patent/ATE388140T1/de not_active IP Right Cessation
- 2003-12-22 ES ES03782471T patent/ES2301859T3/es not_active Expired - Lifetime
- 2003-12-22 KR KR1020057012084A patent/KR20050087868A/ko not_active Application Discontinuation
- 2003-12-22 CN CNB2003801098971A patent/CN100443474C/zh not_active Expired - Fee Related
- 2003-12-22 EP EP03782471A patent/EP1575926B1/en not_active Expired - Lifetime
- 2003-12-22 JP JP2004562819A patent/JP4679154B2/ja not_active Expired - Fee Related
- 2003-12-22 ZA ZA200504943A patent/ZA200504943B/en unknown
- 2003-12-22 PT PT03782471T patent/PT1575926E/pt unknown
- 2003-12-22 NZ NZ540762A patent/NZ540762A/en unknown
- 2003-12-22 WO PCT/EP2003/014722 patent/WO2004058729A1/en active IP Right Grant
- 2003-12-23 CL CL200302746A patent/CL2003002746A1/es unknown
- 2003-12-23 AR ARP030104813A patent/AR042665A1/es unknown
- 2003-12-23 TW TW092136605A patent/TWI287545B/zh not_active IP Right Cessation
- 2003-12-23 MY MYPI20034969A patent/MY140725A/en unknown
-
2004
- 2004-01-05 PE PE2004000042A patent/PE20040937A1/es not_active Application Discontinuation
-
2005
- 2005-06-21 EC EC2005005883A patent/ECSP055883A/es unknown
- 2005-07-25 NO NO20053614A patent/NO20053614L/no not_active Application Discontinuation
- 2005-09-26 HK HK05108489A patent/HK1075629A1/xx unknown
-
2008
- 2008-05-30 CY CY20081100565T patent/CY1107978T1/el unknown
- 2008-10-08 US US12/247,688 patent/US20100204241A9/en not_active Abandoned
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ES2301859T3 (es) | Nuevos derivados de piridazin-3(2h)-ona. | |
AR046445A1 (es) | Derivados de piridazin-3(2h)-ona | |
ECSP066298A (es) | Compuestos 1h-pirazol 3,4-disustituidos y su uso como moduladores de quinasas dependientes de ciclina (cdk) y quinasa-3 de sintasa de glicógeno (gsk-3) | |
AR051738A1 (es) | Derivados de piridazin-3(2h)-ona, composicin farmaceutica, y uso del compuesto para fabricar medicamentos | |
ES2196772T3 (es) | Compuestos amino ciclicos. | |
AR029740A1 (es) | Compuestos derivados de la n-(4-carbamimidoil-fenil)-glicina ,su uso , procedimiento de obtencion de los mismos, preparados farmaceuticos que los contienen y compuestos derivados de la n-(4-ciano-fenil)-glicina | |
ES2213007T3 (es) | Derivados de 4,5-diaril-3(2h)-furanona como inhibidores de la ciclooxigenasa-2. | |
CO5640099A2 (es) | Derivados de oxifenilo aromaticos y de sulfanilfenilo aromaticos | |
AR036107A1 (es) | Derivados de 6-fenilpirrolpirimidindiona, antagonista de los receptores a2 de la adenosina, particularmente del subtipo a2, de aplicacion en la prevencion de la degranulacion de los mastocitos; composiciones farmaceuticas formuladas con dichos compuestos y uso de los mismos en la preparacion de medi | |
CA2423103A1 (en) | N-acylsulfonamide apoptosis promoters | |
AR024969A1 (es) | Derivados de 8-fenil-6,9-dihidro-[1,2,4]triazol[3,4-i]purin-5-ona | |
AR032626A1 (es) | Amidas, composiciones farmaceuticas que las comprenden, proceso para preparar dichas composiciones, uso de dichas amidas en la preparacion de medicamentos, y proceso para la preparacion de dichas amidas | |
AR032453A1 (es) | Derivados alquinil fenil heteroaromaticos activadores de glucoquinasa, un proceso para su preparacion, composiciones farmaceuticas, el uso de dichos derivados para la preparacion de medicamentos | |
ECSP077422A (es) | Derivado de bencimidazol ariloxi-sustituido | |
ES2571327T3 (es) | Composiciones plaguicidas | |
AR068538A1 (es) | Compuesto heterociclico de 5 miembros con actividad supresora de la secrecion de acido | |
WO2006021656A3 (fr) | Derives d'amino- piperidine , leur preparation et leur application en tant qu'agonistes des recepteurs aux melanocortines | |
HUP0401784A2 (hu) | Heterobiciklikus szerkezetû virális polimeráz inhibitorok, eljárás az elõállításukra, köztitermékek és ezeket tartalmazó gyógyszerkészítmények | |
AR031066A1 (es) | Un compuesto que comprende una amida, un proceso para su preparacion, composicion farmaceutica y el uso de dichos compuestos para la preparacion de medicamentos | |
CY1105587T1 (el) | Ισοϊνδολινο-1 -ονη-ενεργοποιητες γλυκοκινασης | |
AR038703A1 (es) | Derivados de 5-feniltiazol y uso como inhibidor de quinasa p i 3 | |
NO20062633L (no) | Pyrazolderivater som proteinkinasemodulatorer | |
AR049402A1 (es) | Derivados de piridazin-3-(2h)-ona | |
RU2010116253A (ru) | Производные n-гидроксилсульфонамида как новые физиологически применимые доноры нитроксила | |
AR036492A1 (es) | Inhibidores de la 17beta-hidroxiesteroide deshidrogenasa tipo 3, composiciones farmaceuticas y el uso de dichos inhibidores para la elaboracion de un medicamento para el tratamiento de enfermedades androgeno dependientes |